The US Drug and Food Administration (US FDA) has issued 3 objections to Lupin's Pithampur plant in Madhya Pradesh. The company's plant was inspected from September 16 to September 27. This plant includes unit-1 API and finished product manufacturing. The company said that the inspection concluded with 3 objections at the API and finished product site. The pharmaceutical company is addressing these objections and will respond to the US FDA within the stipulated time frame.

Mumbai-based Lupin is an innovation-led multinational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in more than 100 markets in the US, India, South Africa and Asia Pacific (APAC), Latin America (LATAM), Europe and the Middle East regions. Stock Performance The company's stock closed 1.56 per cent higher at Rs 2,222.20. The stock's 52-week high is Rs 2,312. In the last one year, the company's stock has seen a gain of 96.13 per cent. During the first quarter of FY 2025, the company's profit grew 76.01 per cent to Rs 801.31 crore. Whereas in the first quarter of FY 2024 it was Rs 452.26 crore.